Surrogate endpoints in assessment of new drugs in colorectal cancer

Lancet

Volumn 356, Issue 9227, 2000, Pages 353-354

  Kelsen, D P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; META ANALYSIS; NOTE; PRIORITY JOURNAL;

EID: 0034729997     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02522-8     Document Type: Note

References (6)

1. CG Moertel TR Fleming JS Macdonald Levamisole and fluorouracil for advanced therapy of resected colon carcinoma N Engl J Med 322 1990 352 358
2. DG Haller PJ Catalano JS Macdonald RJ Mayer Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five‐year final report of INT‐0089 Proc Am Soc Clin Oncol 17 1998 256a 356a
3. MJ O'Connell JA Laurie M Kahn Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high‐risk colon cancer J Clin Oncol 16 1998 295 300
4. LB Saltz J Douillard N Pirotta Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first‐line therapy of previously untreated metastatic colorectal cancer (MCRC) Proc Am Soc Clin Oncol 18 1999 242a 342a
5. JY Douillard D Cunningham AD Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first‐line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
6. A deGramont A Figer M Seymour A randomized trial of leucovorin (LV and 5‐fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC) Proc Am Soc Clin Oncol 17 1998 257a 357a